Skip to content

eLIFEwithIBD - Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease (Online)

eLIFEwithIBD (Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease): The Impact of an ICT-based Intervention on Physical and Mental Health

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05405855
Acronym
eLIFEwithIBD
Enrollment
80
Registered
2022-06-06
Start date
2022-01-05
Completion date
2022-10-15
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Brief summary

This study aims to test the acceptability and preliminary efficacy of an online intervention (eLIFEwithIBD) developed for people with inflammatory bowel disease (IBD). The eLIFEwithIBD intervention is an adaptation of the LIFEwithIBD program (delivered in an in-person group format; Trindade et al., 2021), being an ACT, mindfulness, and compassion-based intervention. The eLIFEwithIBD intervention comprises nine sessions focusing on education about IBD, the functioning of the mind, emotions, and fatigue; acceptance of internal experiences; willingness; emotion regulation; values clarification; committed action; mindfulness; compassion; and gratitude. These topics are addressed through videos with therapists, texts, and experiential exercises.

Interventions

BEHAVIORALeLIFEwithIBD

eLIFEwithIBD program is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients.

Sponsors

University of Coimbra
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* aged between 18 and 65; * IBD diagnosis (at least from 6 months prior); * regular access to a computer with internet; * able to write and read in Portuguese, and give informed consent.

Exclusion criteria

* diagnosis of a psychiatric disorder (major depressive disorder, psychotic disorder, bipolar disorder, substance abuse), or suicidal ideation (assessed by the Patient Health Questionnaire-9); * current psychotherapy use; * pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Psychological distress (DASS-21; Lovibond & Lovibond, 1995)From Baseline to 4-months follow-upThe DASS-21 is a 21-item measure of depressive (e.g., I felt I wasn't worth much as a person), anxiety (e.g., I felt scared without any good reason), and stress (e.g., I found it hard to wind down) symptoms during the precedent week, using a 4-point scale \[ranging from did not apply to me at all (0) to applied to me very much, or most of the time (3)\].

Secondary

MeasureTime frameDescription
Perception of Quality of Life - EUROHIS-QOL 8-item index (Power, 2017); Inflammatory Bowel Disease Questionnaire - UK version (IBDQ-UK; Cheung et al., 2000)From Baseline to 4-months follow-upThe EUROHIS-QOL 8-item index is a quality of life measure composed of eight items (regarding general health, energy, daily living activity, overall quality of life, finances, social relationships, self-esteem, and home) which were extracted from the WHOQOL-Bref. Each item has an individualized 5-point Likert scale (the same response scales used in the WHOQOL-bref). The Inflammatory Bowel Disease Questionnaire-UK version (IBDQ-UK), which is the Anglicized 30-item version of the IBDQ (79, 80), an IBD-specific quality of life instrument. Each item is rated on a 4-point scale (three questions have an additional non-applicable option available) ranging from no, no at all/none (0) to on 8 to 14 days (i.e., more than every other day)/Yes, all of the time (4). Participants are asked to answer questions regarding their IBD and how it has affected their lives during the previous 2 weeks.
Chronic illness-related shame (Chronic Illness-related Shame Scale - CISS, Trindade et al., 2017)From Baseline to 4-months follow-upThe CISS is a 7-item unidimensional scale that was specifically designed to evaluate shame associated with the experience of having a chronic illness and/or its related symptoms (e.g., I feel inadequate because of my illness and symptoms, I'm ashamed of talking with others about my illness or symptoms, I feel that my illness is embarrassing). Each item is rated on a 5-point Likert scale \[fromNever true (0) to Always true (4)\].
IBD symptom perception (IBD symptoms scale, Trindade et al., 2019)From Baseline to 4-months follow-upIBD symptoms scale is a 16-item self-report Portuguese scale which was developed to evaluate the frequency of IBD symptoms during the precedent month (e.g., fatigue, abdominal pain and bloating, flatulence, diarrhea, nausea or vomiting, fever, the urgency to evacuate). Each item is rated on a 7-point scale \[ranging from Never (0) to Always (6)\].
Functional impairment (Work and Social Adjustment Scale - WSAS; Mundt et al., 2002)From Baseline to 4-months follow-upThe Work and Social Adjustment Scale (WSAS) is a 5-item measure of perceived functional impairment in daily activities, such as work, family, interpersonal relations, social and private leisure activities, and home management. Each item is rated on a 9-point scale \[Not at all (0) to Very severely (8)\].

Other

MeasureTime frameDescription
Usability - System Usability Scale (SUS; Brooke, 1986)9 weeksSUS is a 10-item self-report scale aimed to evaluate product and user interface usability (e.g., the confidence and ease of use of the plafaform). Items are rated on a 5-point scale ranging from completely disagree (1) to completely agree (5).
Acceptability and Feasibility - The Acceptability and Feasibility Measures (Weiner et al., 2017)9 weeksA four-item self-report instrument measures the acceptability and feasibility of the intervention. Items are answered using a 5-point Likert scale ranging from completely disagree (1) to completely agree (5).

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026